Robert Wieder
Department of Medicine and New Jersey Medical School Cancer Center
Rutgers New Jersey Medical School
Robert Wieder has not added Biography.
If you are Robert Wieder and would like to personalize this page please email our Author Liaison for assistance.
Phase I/II trial of accutane as a potentiator of carboplatin and paclitaxel in squamous cell carcinomas.
American journal of clinical oncology Oct, 2002 | Pubmed ID: 12393981
Pharmacokinetics and safety of ILX23-7553, a non-calcemic-vitamin D3 analogue, in a phase I study of patients with advanced malignancies.
Investigational new drugs Nov, 2003 | Pubmed ID: 14586212
All-trans retinoic acid potentiates Taxotere-induced cell death mediated by Jun N-terminal kinase in breast cancer cells.
Oncogene Jan, 2004 | Pubmed ID: 14724571
Integrin alpha5beta1 promotes survival of growth-arrested breast cancer cells: an in vitro paradigm for breast cancer dormancy in bone marrow.
Cancer research Jul, 2004 | Pubmed ID: 15231661
Expression of FGF-2 alters focal adhesion dynamics in migration-restricted MDA-MB-231 breast cancer cells.
Breast cancer research and treatment Nov, 2004 | Pubmed ID: 15538042
Insurgent micrometastases: sleeper cells and harboring the enemy.
Journal of surgical oncology Mar, 2005 | Pubmed ID: 15726617
Flavopiridol blocks integrin-mediated survival in dormant breast cancer cells.
Clinical cancer research : an official journal of the American Association for Cancer Research Mar, 2005 | Pubmed ID: 15756030
TUNEL assay as a measure of chemotherapy-induced apoptosis.
Methods in molecular medicine , 2005 | Pubmed ID: 15911970
Microfluidic techniques for single-cell protein expression analysis.
Clinical chemistry Jun, 2006 | Pubmed ID: 16556686
Coordinate loss of fibroblast growth factor 2 and laminin 5 expression during neoplastic progression of mammary duct epithelium.
Human pathology Jan, 2007 | Pubmed ID: 16996573
Influence of prescription benefits on reported pain in cancer patients.
Pain medicine (Malden, Mass.) Nov, 2008 | Pubmed ID: 18346057
CCAAT enhancer-binding protein alpha is a molecular target of 1,25-dihydroxyvitamin D3 in MCF-7 breast cancer cells.
The Journal of biological chemistry Jan, 2009 | Pubmed ID: 19054766
Dual FGF-2 and intergrin alpha5beta1 signaling mediate GRAF-induced RhoA inactivation in a model of breast cancer dormancy.
Cancer microenvironment : official journal of the International Cancer Microenvironment Society Dec, 2009 | Pubmed ID: 19308677
A pilot phase II trial of all-trans retinoic acid (Vesanoid) and paclitaxel (Taxol) in patients with recurrent or metastatic breast cancer.
Investigational new drugs Dec, 2011 | Pubmed ID: 20596747
Determination of single cell surface protein expression using a tagless microfluidic method.
Lab on a chip May, 2012 | Pubmed ID: 22415775
Collagen I provides a survival advantage to MD-1483 head and neck squamous cell carcinoma cells through phosphoinositol 3-kinase signaling.
Anticancer research Feb, 2013 | Pubmed ID: 23393327
Establishing a minority-based community clinical oncology program: the University of Medicine and Dentistry of New Jersey, New Jersey Medical School-university Hospital Cancer Center experience.
Journal of oncology practice / American Society of Clinical Oncology Mar, 2013 | Pubmed ID: 23814524
Prescription coverage in indigent patients affects the use of long-acting opioids in the management of cancer pain.
Pain medicine (Malden, Mass.) Jan, 2014 | Pubmed ID: 24106748
JoVE 소개
Copyright © 2024 MyJoVE Corporation. 판권 소유